SLC5A2 and type 2 diabetes mellitus: Specifically, we aim to determine whether a four-week SGLT-2 inhibitor therapy could produce measurable changes in neuropathic function among T2D patients with early or mild abnormalities and to review how shifts in hydroxyl radical markers relate to these clinical and laboratory findings.